Project Grant R43HL184887
Award Date 8/1/26
Completion Date 7/31/27
Dollars Obligated $397K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Woburn, MA 01801, USA
Similar Awards
- The National Cancer Institute awarded Tiba Biotech LLC $399,300 on September 10, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted delivery of enhanced self-amplifying RNA encoding tumor antigens to the spleen for cancer immunotherapy. Tiba Biotech will combine proprietary enhanced self-amplifying RNA (esRNA) technology with spleen-targeting biodegradable nanoparticles based on molecularly defined dendritic structures to deliver tumor antigen to...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Womens Hospital Inc. $1,242,222 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate non-coding RNAs as therapeutic targets in chronic limb-threatening ischemia. The funded research addresses the pathophysiology of chronic limb-threatening ischemia (CLTI), a leading cause of amputation in adults affecting over 200 million people globally. The project will...
- The National Heart, Lung, and Blood Institute awarded The University of North Texas Health Science Center at Fort Worth $426,550 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a bioengineering modular gene delivery system for lung-targeted transgene expression. The project addresses systemic gene therapy for monogenic lung diseases including cystic fibrosis, alpha-1-antitrypsin deficiency, and pulmonary arterial hypertension. The recipient...
- The National Heart, Lung, and Blood Institute awarded $799,998 to The Trustees of the University of Pennsylvania on August 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiotropic solid lipid nanoparticles (LNPs) as a drug and biologic delivery platform for cardiac therapeutics. The research focuses on engineering and understanding heart-targeting LNPs that accumulate in cardiac tissue at significantly higher concentrations than existing drug delivery...
- The National Heart, Lung, and Blood Institute awarded Emmune Inc. $299,664 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a non-viral gene therapy vector for treating and preventing atherosclerotic cardiovascular disease. Emmune will leverage lipid nanoparticle (LNP) technology to achieve non-immunogenic gene delivery of a therapeutic protein capable of treating and preventing atherosclerosis. The company has discovered a novel approach to...
- The National Heart, Lung, and Blood Institute awarded Cmtx Biotech Inc. $367,988 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lung-specific, sulfonium lipid nanoparticle formulation of Incyclinide (CMT-3/SLNP) for treating acute respiratory distress syndrome in sepsis patients. This Phase I Small Business Technology Transfer project will evaluate the formulation and delivery of CMT-3/SLNP, a chemically modified, non-antibiotic tetracycline...
- The National Heart, Lung, and Blood Institute awarded Coridea, LLC $305,365 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients. The project addresses a clinical gap in lung volume reduction therapy. Current surgical options reach only a fraction of severe emphysema patients: wedge excision LVR surgery is invasive and limits candidate eligibility, while...
- The National Heart, Lung, and Blood Institute awarded Nytricx, Inc. $314,337 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer nitric oxide-releasing intravascular catheters with solid slippery surfaces designed to combat infection and thrombosis in short-term applications. Nytricx, Inc., a self-certified small disadvantaged business headquartered in Athens, Georgia, specializes in nitric oxide release polymer technologies for advanced medical...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $300,000 on July 8, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to support therapeutic preclinical development of TY1, a novel synthetic noncoding RNA drug candidate for scleroderma heart disease. The award funds investigation of TY1's mechanisms in reversing cardiac fibrosis associated with systemic sclerosis, a lethal autoimmune complication. TY1 is a 24-nucleotide chemically-modified...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $405,966 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a multifunctional nanoparticle platform targeting galectin-3 for pulmonary fibrosis therapy. The recipient will optimize anti-fibrotic drug-containing, galectin-3-targeted poly(lactic-co-glycolic acid) nanoparticles for pulmonary delivery, building on prior results demonstrating nanoparticle...